Default company panoramic image
Logo

Bio3 Research srl

Patented use of HMGB1 protein for cardiovascular disease and connective tissue regeneration. Key role of HMGB1 confirmed in patients.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Waltham, MA, USA
  • Currency USD
  • Website bio3research.com

Company Summary

Bio3 has 15 patents on the use of the protein HMGB1 for (a) connective tissue regeneration (diabetic foot ulcers, wound healing, cartilage repair and bone regeneration), and (b) treatment of cardiovascular disorders (atherosclerosis, restenosis, arterial stenosis, and vasculitis). Bio3’s products target significant markets with unmet needs. Bio3’s dietary supplement, Biocysan, treats anemia and oxidative stress in chronic kidney disease patients.

Team

  • Default avatar
    Francesco Paolo Pilato
    CEO

    Dr. Pilato, educated as a chemist, served for more than thirty years at the top executive level in the pharmaceutical and diagnostic industry. Much of his professional experience was in the international arena.

    In the seventies, after a short experience at Lederle Labs, he was appointed Resident Area Manager Middle East at Farmitalia. Later he moved to Japan as Assistant to the Managing Director of Nippon Farmitalia. After his return to Farmit

  • Eccd66bd 18db 4158 8f8e 6147f1635528
    John Piret

Advisors

  • Default avatar
    Bruce M. Landay [Landay Leblang Stern]
    Lawyer
    Unconfirmed